NYSEMKT: OCXOncocyte Corp Stock
$1.80+0.11 (+6.51%)
Updated Jan 24, 2022
OCX Price
$1.80
Fair Value Price
N/A
Market Cap
$166.02M
52 Week Low
$1.62
52 Week High
$6.57
P/E
-4.29x
P/B
1.67x
P/S
70.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.64M
Earnings
-$34.52M
Gross Margin
-30%
Operating Margin
-954.49%
Profit Margin
-743.8%
Debt to Equity
0.69
Operating Cash Flow
-$35M
Beta
1.11
Next Earnings
Mar 14, 2022
Ex-Dividend
N/A
Next Dividend
N/A
OCX Overview
Zen Score
High
Medium
Low
–
Industry Average (19)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OCX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OCX is good value based on its book value relative to its share price (1.67x), compared to the US Biotechnology industry average (4.59x)
Valuation
OCX's cash and short-term investments ($45.96M) cannot cover OCX's cash burn for the next year ($37.04M), once increasing cash burn (124.84%) is accounted for
Financials
OCX's profit margin has increased... subscribe to Premium to read more.
Financials
There are 16 more OCX due diligence checks available for Premium users.
OCX News
Valuation
OCX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.29x
Industry
20.6x
Market
34.17x
OCX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.67x
Industry
4.59x
OCX is good value based... subscribe to Premium to read more.
Valuation
OCX's financial health
Profit margin
Revenue
$984.0k
Net Income
-$13.8M
Profit Margin
-1,402.4%
OCX's cash and short-term investments... subscribe to Premium to read more.
Financials
OCX's profit margin has increased... subscribe to Premium to read more.
Financials
Assets to liabilities
Assets
$168.3M
Liabilities
$69.0M
Debt to equity
0.69
OCX's short-term assets ($47.59M) exceed... subscribe to Premium to read more.
Financials
OCX's long-term liabilities ($55.62M) exceed... subscribe to Premium to read more.
Financials
OCX's debt has increased relative... subscribe to Premium to read more.
Financials
OCX's debt to equity ratio... subscribe to Premium to read more.
Financials
Cash flow
Operating
-$11.0M
Investing
-$394.0k
Financing
$8.2M
OCX's cash and short-term investments... subscribe to Premium to read more.
Financials
Oncocyte Corp Stock FAQ
©2022 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.